SG11202003840QA - Composition for controlled ovarian stimulation - Google Patents

Composition for controlled ovarian stimulation

Info

Publication number
SG11202003840QA
SG11202003840QA SG11202003840QA SG11202003840QA SG11202003840QA SG 11202003840Q A SG11202003840Q A SG 11202003840QA SG 11202003840Q A SG11202003840Q A SG 11202003840QA SG 11202003840Q A SG11202003840Q A SG 11202003840QA SG 11202003840Q A SG11202003840Q A SG 11202003840QA
Authority
SG
Singapore
Prior art keywords
composition
ovarian stimulation
controlled ovarian
controlled
stimulation
Prior art date
Application number
SG11202003840QA
Inventor
Saez Joan-Carles Arce
Lisbeth Helmgaard
Bjarke Mirner Klein
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of SG11202003840QA publication Critical patent/SG11202003840QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202003840QA 2017-09-01 2018-08-31 Composition for controlled ovarian stimulation SG11202003840QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01
PCT/EP2018/073442 WO2019043143A1 (en) 2017-09-01 2018-08-31 Composition for controlled ovarian stimulation

Publications (1)

Publication Number Publication Date
SG11202003840QA true SG11202003840QA (en) 2020-05-28

Family

ID=59772482

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003840QA SG11202003840QA (en) 2017-09-01 2018-08-31 Composition for controlled ovarian stimulation

Country Status (31)

Country Link
US (2) US11744879B2 (en)
EP (3) EP3973982B1 (en)
JP (2) JP6856819B2 (en)
KR (1) KR20200045543A (en)
CN (1) CN111050787A (en)
AR (1) AR112541A1 (en)
AU (1) AU2018326556B2 (en)
BR (1) BR112020003379A2 (en)
CA (1) CA3073624A1 (en)
CL (1) CL2020000482A1 (en)
DK (2) DK3675894T3 (en)
EA (1) EA202090480A1 (en)
ES (1) ES2904787T3 (en)
FI (1) FI3973982T3 (en)
HR (1) HRP20211802T1 (en)
HU (1) HUE056726T2 (en)
IL (1) IL272763B2 (en)
JO (1) JOP20200034A1 (en)
LT (2) LT3973982T (en)
MA (2) MA56224A (en)
MD (1) MD3675894T2 (en)
MX (2) MX2020002235A (en)
PH (1) PH12020500404A1 (en)
PL (1) PL3675894T3 (en)
PT (2) PT3973982T (en)
RS (1) RS62810B1 (en)
SG (1) SG11202003840QA (en)
SI (1) SI3675894T1 (en)
TW (1) TWI749255B (en)
UA (1) UA126869C2 (en)
WO (1) WO2019043143A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237173A (en) * 2020-12-09 2022-10-01 荷蘭商菲林公司 Compositions and methods for controlled ovarian stimulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1442748A1 (en) * 2000-01-27 2004-08-04 Applied Research Systems ARS Holding N.V. Use of FSH for treating infertility
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
WO2009036771A1 (en) * 2007-09-21 2009-03-26 Pharmabrand S.A. Composition comprising mucilaginous polysaccharides derived from aloe barbadensis combined with liposomes, method for obtaining same and use thereof as a sun protector, an anti-acne agent, an epidermal regenerator and a moisturiser
TWI488640B (en) 2008-04-16 2015-06-21 Ferring Int Ct Sa Pharmaceutical preparation
WO2011089602A2 (en) * 2010-01-21 2011-07-28 Ramot At Tel-Aviv University Ltd. Aloe-emodin derivatives and use thereof for the treatment of cancer
PL2621517T5 (en) 2010-09-29 2024-01-29 Ferring B.V. Composition for use in treating infertility
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (en) 2011-08-08 2017-03-15 Ferring Bv Composition for controlled ovarian stimulation
KR20160144480A (en) * 2014-04-18 2016-12-16 글리코토페 게엠베하 Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone
JP7163027B2 (en) 2015-02-26 2022-10-31 フェリング ベスローテン フェンノートシャップ How to treat infertility
EP3662925B1 (en) * 2015-04-17 2021-04-07 Ferring B.V. Composition comprising fsh for treatment of infertility
JP6964519B2 (en) 2015-04-24 2021-11-10 フェリング ベスローテン フェンノートシャップ Gonadotropin manufacturing method
CN107709350A (en) 2015-06-26 2018-02-16 辉凌公司 Purifying and/or the method for inactivation of virus
CN112088011A (en) 2018-04-30 2020-12-15 辉凌公司 Compositions for controlled ovarian stimulation
TWI846743B (en) 2018-10-17 2024-07-01 荷蘭商菲林公司 Compositions and methods for controlled ovarian stimulation

Also Published As

Publication number Publication date
EP3675894B1 (en) 2021-11-03
MX2024009224A (en) 2024-08-06
DK3675894T3 (en) 2022-01-24
MA50034B1 (en) 2022-02-28
US20240024424A1 (en) 2024-01-25
PT3973982T (en) 2024-09-16
BR112020003379A2 (en) 2020-08-25
IL272763B2 (en) 2024-02-01
EP3675894A1 (en) 2020-07-08
FI3973982T3 (en) 2024-09-23
LT3973982T (en) 2024-09-10
MX2020002235A (en) 2020-07-20
CA3073624A1 (en) 2019-03-07
JP2021046398A (en) 2021-03-25
AR112541A1 (en) 2019-11-06
EA202090480A1 (en) 2020-07-20
IL272763B1 (en) 2023-10-01
TWI749255B (en) 2021-12-11
US20200197493A1 (en) 2020-06-25
PT3675894T (en) 2022-01-25
WO2019043143A1 (en) 2019-03-07
DK3973982T3 (en) 2024-09-23
EP3973982A1 (en) 2022-03-30
HUE056726T2 (en) 2022-03-28
MD3675894T2 (en) 2022-03-31
MA50034A (en) 2021-05-12
ES2904787T3 (en) 2022-04-06
EP4427806A2 (en) 2024-09-11
EP3973982B1 (en) 2024-07-31
IL272763A (en) 2020-04-30
CN111050787A (en) 2020-04-21
PH12020500404A1 (en) 2021-03-01
JOP20200034A1 (en) 2020-02-13
HRP20211802T1 (en) 2022-03-04
JP6856819B2 (en) 2021-04-14
UA126869C2 (en) 2023-02-15
LT3675894T (en) 2021-12-10
PL3675894T3 (en) 2022-02-21
MA56224A (en) 2022-04-20
AU2018326556B2 (en) 2024-09-26
US11744879B2 (en) 2023-09-05
KR20200045543A (en) 2020-05-04
TW201919687A (en) 2019-06-01
RS62810B1 (en) 2022-02-28
JP2020528071A (en) 2020-09-17
SI3675894T1 (en) 2022-01-31
EP4427806A3 (en) 2024-10-09
JP7373479B2 (en) 2023-11-02
CL2020000482A1 (en) 2020-06-26
AU2018326556A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
PL3697376T3 (en) Composition
GB201703455D0 (en) Composition
GB2562466B (en) Composition
GB201719139D0 (en) Composition
GB201707238D0 (en) Composition
GB201700504D0 (en) Composition
GB201713636D0 (en) Composition
GB201712151D0 (en) Composition
EP3675653C0 (en) Antimycotoxin composition
IL272763A (en) Composition for controlled ovarian stimulation
GB201721674D0 (en) Composition
GB201718871D0 (en) Composition
GB201709905D0 (en) Composition
IL280750A (en) Compositions and methods for controlled ovarian stimulation
GB201702833D0 (en) Composition
GB201816988D0 (en) Composition
PT3576546T (en) Probiotical composition
GB201715135D0 (en) Composition
GB201711446D0 (en) Composition
GB201707920D0 (en) Composition
GB201703457D0 (en) Composition
PL3576546T3 (en) Probiotical composition
EP3565570C0 (en) Composition
GB201721675D0 (en) Composition
GB201719763D0 (en) Composition